Last updated: February 23, 2026
What is NDC 00378-6854?
NDC 00378-6854 refers to a prescription medication marketed by Novo Nordisk. Specifically, it is Ozempic (semaglutide) injection, indicated for type 2 diabetes management. It has both glucose control and weight management indications.
Market Size and Growth Drivers
Diabetes Market
The global diabetes pharmaceutical market reached approximately $50 billion in 2022. Novo Nordisk commands 45% of this market, driven by its GLP-1 receptor agonist portfolio including Ozempic.
Market Penetration
- US Usage: Estimated 13 million diagnosed type 2 diabetes patients.
- Global Usage: Approximately 537 million adults, with US accounting for roughly 25% of global usage.
- Prescription Trends: Prescriptions for GLP-1 agonists surged over the past five years, with CAGR (compound annual growth rate) around 10%.
Competitive Landscape
- Main competitors include Eli Lilly’s Trulicity, AstraZeneca’s Bydureon, and newer entrants with biosimilar GLP-1s.
- Ozempic maintains premium positioning due to efficacy and brand recognition.
Price Points and Reimbursement
Wholesale Acquisition Cost (WAC)
As of Q1 2023, list price for Ozempic is approximately $900 per 4-week dose (based on a 0.5 mg or 1 mg dose). The typical patient receives a dose of 1 mg weekly, with the monthly cost around $900–$1,200 depending on dosage adjustments and pharmacy discounts.
Reimbursement and Out-of-Pocket Costs
- Average insurer reimbursement aligns with WAC minus a negotiated discount (~20%).
- Patients often pay $25–$50 copay monthly, depending on coverage.
Price Trends
- Since 2018, the price increased at an average of 8% annually.
- The introduction of higher-dose formulations and increased demand underpin sustained price stability.
Regulatory and Patent Status
Patent Landscape
- Patent protection for Ozempic is valid until 2030.
- Novo Nordisk’s patent estate covers manufacturing methods and formulations, securing market exclusivity.
Biosimilar Considerations
- No biosimilars currently approved in the US for semaglutide.
- Patent expiration does not significantly threaten current pricing power before 2030.
Revenue Projections
Short-term (2023–2025)
- Estimated global sales increase at 15% annually driven by growing adoption.
- North America accounts for 60% of sales; Europe and Asia-Pacific showing rapid growth.
Long-term Outlook (2025–2030)
- Potential for sales exceeding $8 billion globally by 2030.
- Market expansion fueled by obesity indications and ongoing clinical trials.
Key Risks and Opportunities
Risks
- Patent litigation or challenged patents could open pathways for biosimilars.
- Price sensitivity and insurance formulary restrictions limit revenue growth.
Opportunities
- Expanded indications for obesity and cardiovascular outcomes.
- Combination therapies within the same class expanding patient access.
Price Projection Summary
| Year |
Estimated WAC per 4-week dose |
Projected Global Sales |
Notes |
| 2023 |
$900 |
$2.2B |
Growth driven by new patients |
| 2025 |
$950 |
$3.5B |
Increasing adoption and dose optimization |
| 2030 |
$1,200 |
$8.2B |
Market penetration in emerging markets |
Price increases are expected to stabilize at around 4-6% annually through 2030, subject to inflation and competitive dynamics.
Conclusion
NDC 00378-6854, Ozempic, commands a leading position in the GLP-1 drug market. Its high price point and patent protection create a favorable revenue outlook through 2030. Price growth will likely match or slightly exceed inflation rates, with substantial upside in expanding indications and markets.
Key Takeaways
- Ozempic remains a dominant GLP-1 therapy with over $2 billion in global sales forecasted for 2023.
- Current US list price is approximately $900 per 4-week dose; patient out-of-pocket costs are substantially lower due to insurance.
- Revenue growth will benefit from expanding indications, though biosimilar competition post-2030 could impact pricing.
- The patent estate secures exclusivity until 2030, supporting sustained pricing power.
- Market expansion globally, especially in Asia and emerging markets, presents future growth opportunities.
FAQs
Q1: Will biosimilars affect Ozempic’s price before 2030?
A: Biosimilar approval is unlikely before patent expiration in 2030, minimizing immediate price competition.
Q2: How do reimbursement policies impact pricing?
A: Reimbursements typically cover a portion of the list price, but negotiated discounts and patient copays influence net revenue.
Q3: What factors could accelerate price increases?
A: New formulations, increased demand, and expanded indications such as obesity management could support higher prices.
Q4: Are there market risks that could dampen sales growth?
A: Patent litigation, insurance formulary constraints, or faster-than-expected biosimilar entry could pose risks.
Q5: How does Ozempic compare to competitors in terms of pricing?
A: Prices are comparable with other GLP-1s, with slight variations based on dose and manufacturer discounts.
References
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] Novo Nordisk. (2023). Ozempic prescribing information.
[3] Centers for Medicare & Medicaid Services. (2023). Reimbursement and formularies.
[4] U.S. Patent and Trademark Office. (2022). Patent Status for Semaglutide.
[5] Grand View Research. (2022). Diabetes Medications Market Size, Share & Trends.
